anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Despite being high health care utilizers, many women Veterans perceive their pain condition to be poorly understood by their providers, which can be a strong demotivator for seeking care. We set out to understand the priorities rural-dwelling women Veterans have for using health care for their chronic pain, and interviewed participants about their experiences with (and priorities for seeking) health care for their chronic pain. Self-Determination Theory identifies three sources of motivation (autonomy, competence, relatedness), all of which were represented through two themes that reflect rural women Veterans' rationale for decision-making to obtain health care for chronic pain: role of trust and competing priorities. Women described their priorities for chronic pain management in terms of their competing priorities for work, education, and supporting their family, but most expressed a desire to function in their daily life and relationships. Second, women discussed the role of trust in their provider as a source of motivation, and the role of patient-provider communication skills and gender played in establishing trust. Rural women Veterans often discussed core values that stemmed from facets of their identity (e.g. gender, military training, ethnicity) that also influenced their decision-making. Our findings provide insight for how providers may use Motivational Interviewing and discuss chronic pain treatment options so that rural-dwelling women Veterans feel autonomous, competent, and understood in their decision-making about their chronic pain. We also discuss importance of acknowledging the effects of disenfranchising talk and perpetuating gendered stereotypes related to chronic pain and theoretical implications of this work.
Exercise counseling 1 time/week. Strength training 3 times/week, dose: 10 RM x 3 sets.
The invention provides a medicine for treating osteosarcoma prepared by combining tripterine and HER2-CAR-T cells, belonging to the field of biological medicine. The medicine has synergistic effect, increases the killing effect on tumor cells, reduces the application dosage and toxic and side effects of HER2-CAR-T cells, and can reduce the medical cost after combined application. The HER2-CAR-T cells are usually administered by injection, while the tripterine is usually administered by intravenous injection, so that the medicine is widely distributed and can reach various parts for treatment. The combination preparation can be used singly or in combination. The medicine contains at least one diluent which can carry carrier substances in pharmacy, such as water, physiological saline, glucose aqueous solution, other non-aqueous solvents and the like, so as to enhance the treatment effect. The medicine can be used for treating malignant tumors including osteosarcoma, esophageal carcinoma, gastric cancer, pancreatic cancer, breast cancer and ovarian cancer.
Participants will receive and consume three daily servings (24 ounces) of plain bottled/canned water in place of their usual commercial diet beverage. The water will be unflavored, unsweetened, non-caloric, and may be plain or sparkling. Participants randomized to consume water will be instructed to avoid intake of diet beverages.
An Orthokeratology lens (OK-lens) is a rigid contact lens with a reverse geometry on its back surface. Overnight OK-lens wearing flattens the central cornea (creating minus power) and steepens the mid-peripheral cornea (creating plus power). During the day, this inverted pattern of peripheral corneal refraction induces relative peripheral myopic defocus on the retina to slow down the axial growth. The central portion of an MFCL is designed with minus powers to correct for distance vision, and plus power is directly added to the peripheral part of the lens. Daytime MFCL wear imposes peripheral retinal myopic defocus when the lenses are worn. An MFCL can also reduce axial growth by 52% compared to a single vision spectacle or contact lens.

Myopia control with OK-lens or MFCL requires a long-term commitment from doctors and patients to see the effect become apparent. It is paramount to estimate the probability that a patient would achieve effective control in myopic progression ideally before treatment begins or early during the course of treatment. To this end, efforts have been made to investigate the correlations between axial growth and possible contributing factors. Early research works have covered a variety of parameters at the baseline, including age, spherical equivalent (SE), corneal eccentricity, and corneal thickness. These measurements are nonspecific, indirect, and based on the assumption that their relationships to axial growth are linear, which often leads to contradictory findings and results that are hard to interpret by physicians. Therefore, in this study, we proposed a new index that takes pupil size into consideration by determining the summed relative myopic defocus dosage within the pupillary area (PMDD) to predict myopia control's success rate. This index will be determined for each eye, will be quantified one month after the lens dispensing, and will be used as the predictive variable.
BACKGROUND: Evidence-based care processes are not always applied at the bedside in critically ill patients. Numerous studies have assessed the impact of checklists and related strategies on the process of care and patient outcomes. We aimed to evaluate the effects of real-time random safety audits on process-of-care and outcome variables in critical care patients.
METHODS: This prospective study used data from the clinical information system to evaluate the impact of real-time random safety audits targeting 32 safety measures in two intensive care units during a 9-month period. We compared endpoints between patients attended with safety audits and those not attended with safety audits. The primary endpoint was mortality, measured by Cox hazard regression after full propensity-score matching. Secondary endpoints were the impact on adherence to process-of-care measures and on quality indicators.
RESULTS: We included 871 patients; 228 of these were attended in ≥ 1 real-time random safety audits. Safety audits were carried out on 390 patient-days; most improvements in the process of care were observed in safety measures related to mechanical ventilation, renal function and therapies, nutrition, and clinical information system. Although the group of patients attended in safety audits had more severe disease at ICU admission [APACHE II score 21 (16-27) vs. 20 (15-25), p = 0.023]; included a higher proportion of surgical patients [37.3 % vs. 26.4 %, p = 0.003] and a higher proportion of mechanically ventilated patients [72.8 % vs. 40.3 %, p < 0.001]; averaged more days on mechanical ventilation, central venous catheter, and urinary catheter; and had a longer ICU stay [12.5 (5.5-23.3) vs. 2.9 (1.7-5.9), p < 0.001], ICU mortality did not differ significantly between groups (19.3 % vs. 18.8 % in the group without safety rounds). After full propensity-score matching, Cox hazard regression analysis showed real-time random safety audits were associated with a lower risk of mortality throughout the ICU stay (HR 0.31; 95 %CI 0.20-0.47).
CONCLUSIONS: Real-time random safety audits are associated with a reduction in the risk of ICU mortality. Exploiting data from the clinical information system is useful in assessing the impact of them on the care process, quality indicators, and mortality.
Placebo syrup once daily for 2 weeks. Both placebo syrups were received by subjects who were randomized to receive placebo. Each subject was instructed to take 2 teaspoons from Bottle A and 2 teaspoons from Bottle B once daily, before 10:00 AM.
An apoptosis inducer for cancer cells containing, as the active ingredient, vegetable tallow (Sapium sebiferum) and/or its extract. An anticancer agent and a food product containing, as the active ingredient, the apoptosis inducer for cancer cells as described above. A metastasis inhibitor for cancer cells containing, as the active ingredient, vegetable tallow and/or its extract. An anticancer agent and a food product containing, as the active ingredient, the metastasis inhibitor for cancer cells as described above. An anti-HIV agent containing, as the active ingredient, vegetable tallow and/or its extract. A food product having an anti-HIV effect containing, as the active ingredient, vegetable tallow and/or its extract.
<P>PROBLEM TO BE SOLVED: To provide a gene transfer agent decomposable by enzymic actions after being incorporated into a cell.  <P>SOLUTION: The gene transfer agent is composed of a cationic gelatin in which a cationic polymer chain is introduced into the side chain of gelatin. A polyacrylamide-based polymer block chain as the cationic polymer chain is bound through an aromatic ring to an amino group of the gelatin. A polyplex is formed by electrostatically binding a negatively charged gene. Since the main chain is composed of the gelatin, the gene transfer agent is decomposed by the enzyme actions in vivo.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Prostate cancer (PC) is one of the most common malignancies worldwide in men, with persistently high numbers dying from this disease. Due to low levels of glycolysis in prostate cancer cell, the uses of 18F-FDG PET/CT to detect prostate cancer and its metastases are limited. Prostate specific membrane antigen (PSMA), as known as folate hydrolase I or glutamate carboxypeptidase II, is overexpressed on the cells of prostatic adenocarcinoma. Various low molecular weight radiopharmaceuticals targeting PSMA such as PSMA-11, PSMA-617 for 68Ga-labeling have been developed. 68Ga-PSMA PET/CT has demonstrated desirable sensitivity and specificity in the detection of prostate cancer lesions, which can find many micro lesions that cannot be identified by CT, MRI and bone scan. 68Ga-P16-093, a novel radiopharmaceutical modified based on 68Ga-PSMA-11, with the urea fragment of a conjugate that employs the HBED-CC chelator for labeling with 68Ga(III). The HBED-based chelating ligand binds the 68Ga3+ ion with high affinity in a pseudo-octahedral N2O4 coordination sphere by its two phenolate O, two amino-acetate carboxylate O, and two amino N donor atoms. This pilot study was prospectively designed to evaluate the diagnostic performance of 68Ga-P16-093 compared with 68Ga-PSMA-11 in the same group of primary prostate cancer patients.
Households represent an important location for transmission of influenza. Rapid delivery of Xofluza may reduce household exposures to influenza among susceptible individuals.This study is a pilot study of a home-based approach to influenza infection control, utilizing self-test kits and rapid home delivery of an antiviral. Households with at least 3 individuals residing there at least 4 days a week, including at least 2 household members that are eligible to take antiviral, will be monitored throughout the influenza season for the onset of a cough or two or more acute respiratory infection symptoms. This study will be conducted in households in the Seattle, WA area for one influenza season, beginning November 1, 2019 and ending April 1, 2020. Household will self-monitor for onset of symptoms throughout the influenza season. When symptoms develop, the participant will self-test for influenza infection using a prepositioned home-testing kit. If negative, the ill participant will provide one self-collected nasal swab specimen. If positive, the ill participant will connect with a healthcare provider via the tele-health app on their smartphone to confirm the influenza diagnosis. Next, if eligible to receive Xofluza, the influenza-positive individual will receive a rapid home delivery of Xofluza within 2-6 hours of the positive test result. All influenza-positive participants will provide a self-collected nasal swab specimen at Study Day 0, Study Day 2-3, and Study Day 5-7. For all illness episodes, the ill individual will complete a questionnaire regarding symptom duration and severity, as well as behavioral changes due to illness.
IMM-101 will be given in combination with standard treatment with either pembrolizumab or nivolumab. The first 3 patients entering the anti-PD1 (pembrolizumab or nivolumab) cohort will receive IMM-101 at an increased dosing interval of every 4 weeks. In the absence of safety concerns for these patients after 3 doses of IMM-101, and following a robust safety review, all subsequent patients recruited to this treatment cohort will switch to the standard, more intensive (2-weekly induction dosing) IMM-101 dosing regimen thereafter.
The utility model relates to a pair of wooden shoes, in particular to a pair of flexible health care wooden shoes, which consists of wooden shoe soles, dustproof bottom layers, foot back bands and ankle side bands which are connected in series with the upper surfaces of the wooden shoe soles and ankle jacket bands. The wooden shoe soles are low at the front parts and high at the back parts and consist of more than two wooden blocks, and all the wooden blocks are transversely placed and arranged in the front-back direction to formthe whole shoe soles. The flexible dustproof bottom layers are attached to the bottom surfaces or the bottom surfaces and the side surfaces of the wooden shoe soles. The pair of the wooden shoes has simple structure, and the wooden shoe soles are flexibly connected through wire ropes and can be naturally bent along with the walking of a person, thereby achieving the effect which is the same with soft rubber soles and further serving the effects of being air-permeable and cool when worn in summer. The dustproof bottom layers can block dust and water on the shoe soles from entering into the wooden shoe soles, thereby keeping foot soles clean. Simultaneously, the foot bands and the ankle jacket bands adopt massage blocks, thereby massaging the corresponding acupuncture points of feet during the walking of the person and serving the effects of body strengthening and health care.
PURPOSE: To investigate the pathophysiology and prognostic significance of acute Henle fiber layer (HFL) hyperreflectivity in placoid diseases by examining its relationship with impaired choroidal flow and persistent photoreceptor disruption.
METHODS: Retrospective-prospective observational study on patients with placoid diseases. Indocyanine green angiography and optical coherence tomography were performed during the acute phase and follow-up. Impaired choroidal flow, HFL hyperreflectivity, and persistent ellipsoid zone disruption, their colocalization index, and their associations with initial and final visual acuity were explored.
RESULTS: Sixteen eyes from eight patients (mean age, 25.3 ± 6.44 years) were included (median follow-up, 13.5 months). Quantitative analysis revealed significant correlations between areas of impaired choroidal flow, HFL hyperreflectivity, and persistent ellipsoid zone disruption (correlation coefficients of 0.69, 0.63, and 0.46, respectively). Impaired choroidal flow area exceeded HFL hyperreflectivity (P = 0.002) and ellipsoid zone disruption (P = 0.003). A noteworthy 94% nonrandom overlap between HFL hyperreflectivity and ellipsoid zone disruption was observed. Worse initial visual acuity correlated with foveal involvement (P = 0.0002), thicker choroid (P = 0.001), larger impaired choroidal flow areas (P = 0.02), and thinner outer retina post lesion inactivation (P = 0.04).
CONCLUSION: Henle fiber layer hyperreflectivity predicted photoreceptor recovery potential in placoid diseases. If HFL hyperreflectivity corresponds to acute HFL damage, it may suggest more severe involvement of the entire photoreceptor length.
INTRODUCTION/AIMS: Despite treatment, a considerable proportion of patients with Guillain-Barré syndrome (GBS) experience poor recovery, highlighting a therapeutic need. There is a lack of evidence that treatment timing affects recovery. This study aims to investigate the effects of intravenous immunoglobulin (IVIg) timing on disability and speed of recovery in GBS.
METHODS: We performed a retrospective study of 136 IVIg-treated GBS patients admitted to two Korean centers between 2010 and 2021. We analyzed the effect of time to IVIg on the GBS disability scale (GBS-DS) and the degree of improvement from nadir (∆GBS-DS) at 1, 3, 6, and 12 months, as well as the time to regain the ability to walk or run unaided. Time to IVIg was treated either as a continuous variable or categorized into 1-week intervals to explore critical time windows. Known prognostic factors, the modified Erasmus GBS Outcome Scores on admission and pre-treatment serum albumin levels were adjusted as covariates.
RESULTS: Shorter time to IVIg was independently associated with better GBS-DS, greater ∆GBS-DS, and shorter time to walk or run unaided at all time points. The therapeutic effect of IVIg was notably diminished when administered beyond the first 2 weeks of onset.
DISCUSSION: Our study highlights the timing of IVIg as a modifiable prognostic factor in GBS. The earlier IVIg is initiated, the better the outcomes, with the ideal time window being within the first 2 weeks. These findings underscore the importance of prompt diagnosis and early intervention to optimize recovery in GBS patients.
Sham stimulation will be delivered over to parieto-occipital sites using only 2-minute ramp up and down, without any sinusoidal current administered for 20 minutes. The stimulation electrode montage will be identical for both conditions.
The cpds may contain one or more antibodies directed to a viral antigen, or may contain the antigen itself for the induction of anitbody formation. 34 prefd polymers are listed, eg carbohydrates, amino acids, polyalkane, polycarbonate, polyamide, polysaccharides, etc. The anionic gp is an ester of mineral acids, esp sulphate-and phosphate gps, sulphonate gps, phosphonate gps and carboxylate gps. The carrier (0.1-100 microns) is latex, polysaccharides, lipid vesicles, organic and inorganic polymers, bacterial and viral ghosts and/or cell wall components from blood cells. USE/ADVANTAGE - The cpds are used for prophylaxis and treatment of viral infections (eg HIV), and Alzheimers disease transmissible by animals. The method is effective in cells preforming endocytosis, eg leukocytes, fibroblasts, macrophages, myeloid and non-myeloid phagocytic cells
PROBLEM TO BE SOLVED: To obtain an antiageing agent containing the extract of a leguminous plant, Sophora flavescens Aiton, having an esterase-inhibiting action, and enabling to hold the tension and elasticity of skin and retain the young state of the skin. SOLUTION: This antiageing agent contains the solvent extract of a leguminous plant, Sophora flavescens Aiton, as an active ingredient in an amount of 0.0005-20wt.%, preferably 0.001-10wt.%, based on the whole amount of the agent for external use as a dry product. The extract is especially obtained by immersing the roots of Sophora flavescens Aiton in an extraction solvent (e.g. 1,3-butylene glycol) or thermally refluxing the mixture, filtering and subsequently concentrating the filtrate. Basic cosmetics, make-up cosmetics, hair cosmetics, bath articles, toiletry products, etc., can be prepared. The extract of the Sophora flavescens Aiton exhibits an esterase-inhibiting activity, inhibits the denaturation of elastin which is an elastic fiber, has good elasticity and enables to maintain the skin free from wrinkles and looseness.
Participants will receive 12 cycles of treatment (each cycle is 28 days). Venetoclax (VEN) will be administered orally, daily, with a 5-week ramp-up period, starting on Cycle 1, Day 22 and administration will continue until the end of Cycle 12. Obinutuzumab (G) will be administered intravenously (IV) on Days 1 (and 2), 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
BACKGROUND AND PURPOSE: Scientists have been exploring anti-angiogenic strategies to inhibit angiogenesis and prevent tumor growth. Vasculogenic mimicry (VM) in glioblastoma multiforme (GBM) poses a challenge, complicating anti-angiogenesis therapy. A novel drug, GN25 (3-[{1,4-dihydro-5,8-dimethoxy-1,4-dioxo-2-naphthalenyl}thio]-propanoic acid), can inhibit tumor formation. This study aims to investigate the microenvironmental effects and molecular mechanisms of GN25 in anti-angiogenesis and anti-VM.
EXPERIMENTAL APPROACH: MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) assay was used to evaluate the cell viability of different concentrations of GN25 in human umbilical vein endothelial cells (HUVEC) and Uppsala 87 malignant glioma (U87MG) cells. Functional assays were used to investigate the effects of GN25 on angiogenesis-related processes, whereas gelatin zymography, enzyme-linked immunosorbent assays, and Western blotting were utilized to assess the influence on matrix metalloproteinase (MMP)-2 and vascular endothelial growth factor (VEGF) secretion and related signaling pathways.
KEY RESULTS: GN25 suppressed migration, wound healing, and tube formation in HUVECs and disrupted angiogenesis in a rat aorta ring and zebrafish embryo model. GN25 dose-dependently reduced phosphatidylinositol 3-kinase/AKT and inhibited MMP-2/VEGF secretion in HUVECs. In U87MG cells, GN25 inhibited migration, wound healing, and VM, accompanied by a decrease in MMP-2 and VEGF secretion. The results indicate that GN25 effectively inhibits angiogenesis and VM formation in HUVECs and U87MG cells without affecting preexisting vascular structures.
CONCLUSION AND IMPLICATIONS: This study elaborated GN25's potential as an anti-angiogenic agent by elucidating its inhibitory effects on classical angiogenesis. VM provides valuable insights for developing novel therapeutic strategies against tumor progression and angiogenesis-related diseases. These results indicate the potential of GN25 as a promising candidate for angiogenesis-related diseases.
Pregnancy Category X [see Contraindications (4)]

MULTAQ may cause fetal harm when administered to a pregnant woman. In animal studies, dronedarone was teratogenic in rats at the maximum recommended human dose (MRHD), and in rabbits at half the MRHD. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. 

When pregnant rats received dronedarone at oral doses greater than or equal to the MRHD (on a mg/m2 basis), fetuses had increased rates of external, visceral and skeletal malformations (cranioschisis, cleft palate, incomplete evagination of pineal body, brachygnathia, partially fused carotid arteries, truncus arteriosus, abnormal lobation of the liver, partially duplicated inferior vena cava, brachydactyly, ectrodactylia, syndactylia, and anterior and/or posterior club feet). When pregnant rabbits received dronedarone, at a dose approximately half the MRHD (on a mg/m2 basis), fetuses had an increased rate of skeletal abnormalities (anomalous ribcage and vertebrae, pelvic asymmetry) at doses ≥20 mg/kg (the lowest dose tested and approximately half the MRHD on a mg/m2 basis).

Actual animal doses: rat (≥80 mg/kg/day); rabbit (≥20 mg/kg)
The invention relates to preparation of an artificially synthesized antibacterial lipopeptide LP21 and application thereof in treating bacterial infection, belonging to the field of biological medicine. The sequence of the antibacterial lipopeptide from the N end to the C end is C 8 H 15 O‑WKKLLKWWLKKFKKLD. The antimicrobial lipopeptides are prepared based on key biological characteristics of antimicrobial peptides (positive charge, alpha-helical structure and amphiphilicity). The invention provides a solid-phase synthesis method of the antibacterial lipopeptide. The antibacterial lipopeptide disclosed by the invention has excellent antibacterial activity (the MIC values of escherichia coli ATCC25922 and staphylococcus aureus ATCC29213 are 3 mu M and 0.2 mu M respectively), and has good serum stability and biocompatibility. In vivo antibacterial experiments show that the antibacterial lipopeptide LP21 shows excellent antibacterial efficacy in a mouse in vivo bacterial infection model, is an antibiotic substitute with application potential, and has good application prospects.